Savara Inc (NASDAQ:SVRA) — Market Cap & Net Worth
Market Cap & Net Worth: Savara Inc (SVRA)
Savara Inc (NASDAQ:SVRA) has a market capitalization of $1.10 Billion ($1.10 Billion) as of September 15, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #8512 globally and #2469 in its home market, demonstrating a -0.56% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Savara Inc's stock price $5.34 by its total outstanding shares 205460015 (205.46 Million). Also see SVRA total assets for a full breakdown of the balance sheet.
Savara Inc Market Cap History: 2015 to 2026
Savara Inc's market capitalization history from 2015 to 2026. Data shows change from $6.04 Billion to $1.10 Billion (-15.69% CAGR). Also see SVRA cash flow conversion for how efficiently the company converts equity into cash flow.
Index Memberships
Savara Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.68 Trillion | 0.04% | #249 of 976 |
|
NASDAQ Composite
IXIC
|
$41.94 Trillion | 0.00% | #918 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.89 Trillion | 0.06% | #145 of 263 |
Weight: Savara Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Savara Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Savara Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Savara Inc (SVRA) stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
254770.42x
Savara Inc's market cap is 254770.42 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $1.25 Billion | $400.00K | -$10.92 Million | 3120.94x | N/A |
| 2020 | $236.28 Million | $257.00K | -$49.62 Million | 919.37x | N/A |
| 2021 | $254.77 Million | $1.00K | -$43.01 Million | 254770.42x | N/A |
Competitor Companies of SVRA by Market Capitalization
Companies near Savara Inc in the global market cap rankings as of September 15, 2026. Review Savara Inc (SVRA) tangible equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Savara Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #186 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #338 globally with a market cap of $80.28 Billion USD.
- CSL Ltd (AU:CSL): Ranked #463 globally with a market cap of $58.90 Billion USD ( AU$83.24 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #509 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #186 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $519.51 |
| #338 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $80.28 Billion | $793.74 |
| #463 | CSL Ltd | AU:CSL | $58.90 Billion | AU$171.57 |
| #509 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $146.69 |
Savara Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Savara Inc's market cap moved from $6.04 Billion to $ 1.10 Billion, with a yearly change of -15.69%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.10 Billion | -11.44% |
| 2025 | $1.24 Billion | +96.42% |
| 2024 | $630.76 Million | -34.68% |
| 2023 | $965.66 Million | +203.23% |
| 2022 | $318.46 Million | +25.00% |
| 2021 | $254.77 Million | +7.83% |
| 2020 | $236.28 Million | -74.33% |
| 2019 | $920.46 Million | -40.82% |
| 2018 | $1.56 Billion | -48.99% |
| 2017 | $3.05 Billion | +144.24% |
| 2016 | $1.25 Billion | -79.35% |
| 2015 | $6.04 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 15th, 2026 the market cap of Savara Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.10 Billion USD |
| MoneyControl | $1.10 Billion USD |
| MarketWatch | $1.10 Billion USD |
| marketcap.company | $1.10 Billion USD |
| Reuters | $1.10 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Savara Inc
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. was founded in 2007 and is headquartered in Yardley, P… Read more